These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33848589)

  • 21. Bringing in vitro analysis closer to in vivo: Studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling.
    Verheijen M; Schrooders Y; Gmuender H; Nudischer R; Clayton O; Hynes J; Niederer S; Cordes H; Kuepfer L; Kleinjans J; Caiment F
    Toxicol Lett; 2018 Sep; 294():184-192. PubMed ID: 29803840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic evaluation of high-throughput PBK modelling strategies for the prediction of intravenous and oral pharmacokinetics in humans.
    Geci R; Gadaleta D; de Lomana MG; Ortega-Vallbona R; Colombo E; Serrano-Candelas E; Paini A; Kuepfer L; Schaller S
    Arch Toxicol; 2024 May; ():. PubMed ID: 38722347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrating in vitro data and physiologically based kinetic modeling-facilitated reverse dosimetry to predict human cardiotoxicity of methadone.
    Shi M; Bouwmeester H; Rietjens IMCM; Strikwold M
    Arch Toxicol; 2020 Aug; 94(8):2809-2827. PubMed ID: 32367273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PBK modelling of topical application and characterisation of the uncertainty of C
    Li H; Reynolds J; Sorrell I; Sheffield D; Pendlington R; Cubberley R; Nicol B
    Toxicol Appl Pharmacol; 2022 May; 442():115992. PubMed ID: 35346730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Next Generation Risk Assessment of the Anti-Androgen Flutamide Including the Contribution of Its Active Metabolite Hydroxyflutamide.
    van Tongeren TCA; Carmichael PL; Rietjens IMCM; Li H
    Front Toxicol; 2022; 4():881235. PubMed ID: 35722059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity.
    Yuan A; Wu J; Song C; Tang X; Qiao Q; Zhao L; Gong G; Hu Y
    J Pharm Sci; 2013 May; 102(5):1626-35. PubMed ID: 23423631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice.
    Gao ZG; Lee DH; Kim DI; Bae YH
    J Drug Target; 2005 Aug; 13(7):391-7. PubMed ID: 16308207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic evaluation of intraperitoneal doxorubicin in rats.
    Nagai K; Nogami S; Egusa H; Konishi H
    Pharmazie; 2014 Feb; 69(2):125-7. PubMed ID: 24640601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation and in vitro/in vivo evaluation of doxorubicin-loaded poly[lactic-co-glycol acid] microspheres using electrospray method for sustained drug delivery and potential intratumoral injection.
    Hsu MY; Huang YT; Weng CJ; Chen CM; Su YF; Chu SY; Tseng JH; Wu RC; Liu SJ
    Colloids Surf B Biointerfaces; 2020 Jun; 190():110937. PubMed ID: 32155454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Augmentation of hepatic doxorubicin extraction with extracorporeal filtration avoids the dose-dependent, nonlinear increase in AUC observed with systemic administration.
    Sturgill MG; Brenner DE; August DA
    Cancer Chemother Pharmacol; 1998; 41(3):193-200. PubMed ID: 9443635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of safety parameters and changes in serum concentration in liver transplant recipients treated with doxorubicin during the anhepatic period.
    Kobayashi S; Wada H; Hama N; Akita H; Kawamoto K; Eguchi H; Umeshita K; Doki Y; Mori M; Nagano H
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1325-33. PubMed ID: 24121480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity.
    El-Demerdash E; Ali AA; Sayed-Ahmed MM; Osman AM
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):411-6. PubMed ID: 12879278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrating in vitro data and physiologically based kinetic (PBK) modelling to assess the in vivo potential developmental toxicity of a series of phenols.
    Strikwold M; Spenkelink B; de Haan LHJ; Woutersen RA; Punt A; Rietjens IMCM
    Arch Toxicol; 2017 May; 91(5):2119-2133. PubMed ID: 27815601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Method of hyperthermia and tumor size influence effectiveness of doxorubicin release from thermosensitive liposomes in experimental tumors.
    Willerding L; Limmer S; Hossann M; Zengerle A; Wachholz K; Ten Hagen TL; Koning GA; Sroka R; Lindner LH; Peller M
    J Control Release; 2016 Jan; 222():47-55. PubMed ID: 26658073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection.
    Räsänen M; Degerman J; Nissinen TA; Miinalainen I; Kerkelä R; Siltanen A; Backman JT; Mervaala E; Hulmi JJ; Kivelä R; Alitalo K
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13144-13149. PubMed ID: 27799559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection.
    Ren S; Li C; Dai Y; Li N; Wang X; Tian F; Zhou S; Qiu Z; Lu Y; Zhao D; Chen X; Chen D
    J Pharm Pharmacol; 2014 Sep; 66(9):1231-9. PubMed ID: 24716458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure.
    Siebel C; Würthwein G; Lanvers-Kaminsky C; André N; Berthold F; Castelli I; Chastagner P; Doz F; English M; Escherich G; Frühwald MC; Graf N; Groll AH; Ruggiero A; Hempel G; Boos J
    BMC Pharmacol Toxicol; 2020 May; 21(1):37. PubMed ID: 32466789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ADME characterization and PBK model development of 3 highly protein-bound UV filters through topical application.
    Li H; Bunglawala F; Hewitt NJ; Pendlington R; Cubberley R; Nicol B; Spriggs S; Baltazar M; Cable S; Dent M
    Toxicol Sci; 2023 Oct; 196(1):1-15. PubMed ID: 37584694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integration of cardiac energetics, function and histology from isolated rat hearts perfused with doxorubicin and doxorubicin-ol; a model for use in drug safety evaluations.
    Henderson KA; Borders RB; Ross JB; Abdulalil A; Gibbs S; Skowronek AJ; Knostman K; Bailey J; Smith J; Vinci T; Wood B; Knopp MV; Roche BM
    J Pharmacol Toxicol Methods; 2018; 94(Pt 2):54-63. PubMed ID: 30195582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.